AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04560634
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
Trial: NCT02845752
Drug: Placebo Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation spray
Trial: NCT00314574
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
Trial: NCT00314574
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
Trial: NCT00314574
Drug: long-acting beta-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg salmeterol twice daily or 12 µg formoterol twice daily.
Trial: NCT00951431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the form of study drug
Trial: NCT01334658
Drug: Glucose-bicarbonate-Ringer Lactate (GBRL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Trial: NCT01373749
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation was performed as the only treatment for PPHN during the whole course.
Trial: NCT03172936
Drug: MIW815
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIW 815 (ADU-S100) is a STING agonist
Trial: NCT01578928
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02619695
Drug: Fastjel
RxNorm normalized name: diphenhydramine citrate / pseudoephedrine hydrochloride Disintegrating Oral Tablet [Benadryl-D Fastmelt Allergy and Sinus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
Trial: NCT01869192
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2 d1 q3w
Trial: NCT01869192
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2/dose bid x 14d q3w
Trial: NCT00640705
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Trial: NCT00640705
Drug: Matching placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Trial: NCT02462967
Drug: GR-MD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
Trial: NCT02462967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for GR-MD-02
Trial: NCT00002524
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002524
Drug: Doxorubicin Hydrochloride (DOX)
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002524
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002524
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002524
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01203072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral tablets, once daily for 2 weeks
Trial: NCT01968018
Drug: Tramadol HCI/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
Trial: NCT01450410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment will last for 12 weeks.
Trial: NCT00378014
Drug: CNI
RxNorm normalized name: Acnigel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Trial: NCT00654069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every 6 hours for 48 hours
Trial: NCT00654069
Drug: Acurox 5/30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every 6 hours for 48 hours
Trial: NCT00654069
Drug: Acurox 7.5/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every 6 hours for 48 hours
Trial: NCT00889343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
Trial: NCT00889343
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
Trial: NCT01256177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Trial: NCT06419283
Drug: standard treatment with aspirin.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment with aspirin.
Trial: NCT01071928
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
Trial: NCT03283020
Drug: RemifentanilMNTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Trial: NCT03283020
Drug: PlaceboMNTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Trial: NCT02284503
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive intensive Rosuvastatin before and after PCI
Trial: NCT04504383
Drug: PN-943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by the oral route BID for the duration of the study.
Trial: NCT04504383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by the oral route BID for 12 weeks.
Trial: NCT00273728
Drug: hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
Trial: NCT01325779
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous heparin 5000 units every 8 hours
Trial: NCT00849966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Trial: NCT01782651
Drug: Lapatinib plus capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine
Trial: NCT05291364
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
Trial: NCT05291364
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
Trial: NCT01893424
Drug: Sativex buccal spray
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buccal spray
Trial: NCT02388984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
Trial: NCT00210314
Drug: high dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00358462
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: two 500mg tablets or four 250mg tablets administered as a single dose
Trial: NCT00358462
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 100mg capsule administered twice daily for seven days
Trial: NCT00949624
Drug: CP-868,596
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet 60 mg BID continuous
Trial: NCT00949624
Drug: CP-868,596
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet 100 mg BID continuous
Trial: NCT00706836
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of matched oral placebo to be administered one hour prior to fMRI scan
Trial: NCT01650363
Drug: Homeopathic placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-3 mm small spheric suger pils
Trial: NCT02131480
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m²
Trial: NCT02736656
Drug: SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01624428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg bid placebo titrated over a 2 week period
Trial: NCT01354496
Drug: LY2409021 Reference Form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01354496
Drug: LY2409021 Test-Med Formulation (medium particle size)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01054638
Drug: HAART Treatment
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.
Trial: NCT03080103
Drug: Antibiotic-first therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with antibiotics as first-line approach
Trial: NCT00972803
Drug: pistacia Mutica extract
RxNorm normalized name: Pistacia lentiscus resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
Trial: NCT00972803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were asked to use a placebo mouthwash twice a day for 4 days.
Trial: NCT03117972
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles
Trial: NCT03117972
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles
Trial: NCT03117972
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles
Trial: NCT03117972
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintenance chemotherapy
Trial: NCT01393743
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00717769
Drug: SUN13834
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose, orally 3 times a day (tid) for 28 days of SUN13834
Trial: NCT00717769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally (tid) for 28 days of SUN13834
Trial: NCT03400033
Drug: Matching placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Trial: NCT03400033
Drug: Saline vials or bags
RxNorm normalized name: Rosula NS Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride saline vials or bags administered by the IV route.
Trial: NCT01622946
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
Trial: NCT02248090
Drug: AZD9496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9496
Trial: NCT02248090
Drug: AZD9496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
Trial: NCT03234738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive
Trial: NCT01664013
Drug: Nuronox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
Trial: NCT01596764
Drug: Placebo of MNTX and NLX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
Trial: NCT03238911
Drug: Iron isomaltoside/ferric derisomaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).
Trial: NCT00268138
Drug: elmex gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: elmex gel once a week
Trial: NCT03256552
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation Aerosol
Trial: NCT01670357
Drug: DA-6034 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Trial: NCT01670357
Drug: DA-6034 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Trial: NCT01670357
Drug: DA-6034 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Trial: NCT02203812
Drug: Probiotic Arm
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
Trial: NCT02203812
Drug: Placebo Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
Trial: NCT02259933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01404091
Drug: LY2940094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04355962
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
Trial: NCT04488705
Drug: ETD002 - single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of ETD002
Trial: NCT04488705
Drug: Placebo - single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo
Trial: NCT04488705
Drug: Placebo - 7 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily doses of Placebo for 7 days
Trial: NCT04488705
Drug: Placebo - 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily doses of Placebo for 14 days
Trial: NCT02884089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01452412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be taken on the same schedule as the active arm
Trial: NCT00793767
Drug: placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v
Trial: NCT01358227
Drug: PR104
RxNorm normalized name: PR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
Trial: NCT01465464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet was administered orally twice per day after meals, morning and evening.
Trial: NCT00000403
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03458130
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonactive control
Trial: NCT02505633
Drug: lidocaine mixed with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
Trial: NCT00547703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
Trial: NCT03495882
Drug: AGEN1884 + AGEN2034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGEN1884 + AGEN2034 according to protocol design
Trial: NCT01443247
Drug: anti-d
RxNorm normalized name: D-Gam Anti-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
Trial: NCT00437684
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/50 mg 2 cpr bid monotherapy
Trial: NCT01590407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01528241
Drug: ABP688
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Trial: NCT02375672
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion